SAN FRANCISCO — Efgartigimod (Vyvgart), a neonatal Fc receptor (FcRn) antagonist, significantly improved symptoms in patients with anti-acetylcholine receptor antibody (AChR-Ab)-negative generalized ...

Cemdisiran could be the first siRNA approved for the treatment of gMG and only therapy to be offered subcutaneously with four times a year dosing ...

A growing number of new treatments for myasthenia gravis (MG) are changing how doctors manage the disease and offering new options for people whose symptoms arent fully controlled. In recent years, ...

New guidelines and advocacy enhance myasthenia gravis treatment access, promoting proactive management and improved insurance coverage for diverse patient populations. There are key systemic factors ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. An mRNA‑based CAR T therapy called Descartes‑08 is giving many people with myasthenia gravis ...

Amgen (AMGN) announced that the FDA has approved Uplinza, inebilizumab-cdon, for the treatment of generalized myasthenia gravis, gMG, in adults who are anti-acetylcholine receptor and anti-muscle ...

Christyn Edmundson, MD, is a neurology and neuromuscular medicine specialist with the Providence Swedish Neuroscience Institute in Seattle. Myasthenia gravis (MG) is a neuromuscular condition that can ...

Experts discuss personalized myasthenia gravis treatment, emphasizing patient education and engagement for optimal care and advocacy in managing this variable disease. Personalizing treatment for ...

Myasthenia gravis (MG) is a rare autoimmune disease in which the immune system attacks the connection between nerves and muscles. This attack causes muscle weakness that can affect vision, movement, ...

In a post-conference reflection, Katherine Ruzhansky, MD, explains how the myasthenia gravis (MG) treatment landscape is rapidly evolving, with multiple novel, targeted therapies such as FcRn ...

Three drugs that inhibit the immunoglobulin G (IgG) neonatal fragment crystallizable receptor (FcRn) were approved to treat generalized myasthenia gravis (MG) in recent years: efgartigimod (Vyvgart), ...